Press Releases
Definiens Launches Cloud-based Digital Pathology Solution VeriTrova™ to Support Takeda’s Translation(1)
SAN DIEGO, CA, UNITED STATES - Dec 22, 2016 - Munich, Germany - Dec 22 2016 - Definiens, the leader in Tissue Phenomics® solutions from biomarker discovery to meaningful diagnostics, today announced a program collaboration with Takeda Pharmaceuticals to enable comprehensive tissue-based analysis in clinical trials.
Definiens products and services deepen the understanding of disease biology and the immune system to advance clinical trials. By using knowledge-driven biomarker analysis in combination with VeriTrova, the companys new cloud-based digital pathology platform, Definiens seamlessly translates research to clinical knowledge to the next generation of diagnostics.
As an early adopter of Definiens VeriTrova, Takeda will have the opportunity to leverage the platform to support its development programs.
VeriTrova accelerates clinical trials through remote uploading and viewing of digitized IHC images from wet-lab partners and CROs to the cloud, where the images are analyzed, says Thomas Colarusso, VP Business Development and Strategy at Definiens.
The real-time analysis is expected to help Takeda reduce normal processes from months to weeks, with image analysis providing a more automated and standardized readout.
Takeda is dedicated to operational excellence and delivering high quality results in our clinical studies, says Andrew Dorner, VP and Global Head of Translational Medicine at Takeda. We expect this system will improve the timelines and quality of our image analysis for clinical biomarkers.
For more information about Definiens, visit www.definiens.com.
About Definiens
We improve patient lives by unlocking the tissue phenome. In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer.
Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.
Lina Willis
lwillis@definiens.com
